Needham & Company LLC Cuts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $18.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target dropped by stock analysts at Needham & Company LLC from $20.00 to $18.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 162.39% from the company’s current price.

A number of other research analysts also recently commented on BCRX. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. TD Cowen began coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target on the stock. Cantor Fitzgerald lifted their price objective on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Evercore ISI reiterated an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Finally, JMP Securities upped their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.00.

BioCryst Pharmaceuticals Trading Down 6.3%

NASDAQ:BCRX opened at $6.86 on Tuesday. The business’s fifty day moving average price is $7.56 and its 200 day moving average price is $8.69. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -38.11 and a beta of 1.05. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. BioCryst Pharmaceuticals’s quarterly revenue was up 36.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.07) earnings per share. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of the business’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd grew its stake in BioCryst Pharmaceuticals by 29.3% during the third quarter. Y Intercept Hong Kong Ltd now owns 434,531 shares of the biotechnology company’s stock worth $3,298,000 after buying an additional 98,436 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its position in BioCryst Pharmaceuticals by 128.8% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 41,169 shares of the biotechnology company’s stock worth $312,000 after purchasing an additional 23,177 shares during the period. QTR Family Wealth LLC lifted its position in BioCryst Pharmaceuticals by 3.4% during the 3rd quarter. QTR Family Wealth LLC now owns 157,137 shares of the biotechnology company’s stock valued at $1,193,000 after purchasing an additional 5,151 shares during the period. Csenge Advisory Group acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $190,000. Finally, State of Alaska Department of Revenue acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter worth $90,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.